Nasdaq
$0.9600▼ 1.81%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $27.8MShares out 28.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 4d agoAfter-hours26.10.21 06:0810-QEarnings#●●●#●●●
Celularity Inc
Celularity Inc. reported its financial results for the second quarter ended June 30, 2026. During this period, the company adjusted its business structure through various license and asset purchase agreements. Management certified that the financial statements for this quarter fairly present the company's financial condition and operating results.…more
$0.9600-1.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoPre-market26.10.20 22:1510-K/AEarnings
Celularity Inc
Celularity Inc. filed an amendment to its 2025 Annual Report (Form 10-K/A) to include required Part III information. The filing provides updated details regarding the company's executive officers, board of directors, and the specific terms and limitations of the Series A Convertible Preferred Stock issued in October 2025.…more
$0.9600-1.81%vs prev closeView filingShare - 9.29After-hours26.09.30 06:258-KKey event
Celularity Inc
Celularity Inc. announced on September 29, 2026, the appointment of Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors. This appointment is part of the company's previously announced capital structure improvement and strategic repositioning, coinciding with the resignation of board member Diane Parks.…more
$0.9600-1.81%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:06#●●●
Celularity Regains Nasdaq Compliance
Celularity has regained compliance with Nasdaq's listing rules after successfully filing its required periodic financial reports. This development resolves the company's previous non-compliance status regarding SEC reporting obligations.…more
$0.9600-1.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30Regular26.10.01 00:57
●●●●●●●● ●●●●● ●●●●●●
Celularity is collaborating on the Fontaine Vitale regenerative medicine center in Bali, scheduled to open in Q1 2027. While the company aims to supply its cellular therapies to the facility, specific commercial terms and revenue impacts remain subject to future agreements.…more
$0.9600-1.81%vs prev close - 9.29After-hours26.09.30 06:32
●●●●●●●● ●●●●● ●●●●●●
Celularity reported a Q1 EPS of $0.02, marking a turnaround from the previous year's loss. However, quarterly revenue fell significantly to $3.846 million, representing a 66% decline compared to the same period last year.…more
$0.9600-1.81%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report